
Paul B Fisher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2435255/publications.pdf Version: 2024-02-01



DALLI R FICHED

#	Article	IF	CITATIONS
1	GAP junctions: multifaceted regulators of neuronal differentiation. Tissue Barriers, 2022, 10, 1982349.	1.6	5
2	Dissecting the Balance Between Metabolic and Oncogenic Functions of Astrocyteâ€Elevated Geneâ€1/Metadherin. Hepatology Communications, 2022, 6, 561-575.	2.0	4
3	Screening of the Prime bioactive compounds from Aloe vera as potential anti-proliferative agents targeting DNA. Computers in Biology and Medicine, 2022, 141, 105052.	3.9	13
4	Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor. Frontiers in Oncology, 2022, 12, 812560.	1.3	2
5	Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter. Cancers, 2022, 14, 1497.	1.7	1
6	Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein. International Journal of Molecular Sciences, 2022, 23, 72.	1.8	5
7	Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Advances in Cancer Research, 2021, 149, 1-61.	1.9	330
8	Autophagy and senescence: Insights from normal and cancer stem cells. Advances in Cancer Research, 2021, 150, 147-208.	1.9	5
9	Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Advances in Cancer Research, 2021, 152, 329-381.	1.9	3
10	Preface. Advances in Cancer Research, 2021, 150, xiii-xviii.	1.9	0
11	Metabolic control of cancer progression as novel targets for therapy. Advances in Cancer Research, 2021, 152, 103-177.	1.9	5
12	Theranostic Tripartite Cancer Terminator Virus for Cancer Therapy and Imaging. Cancers, 2021, 13, 857.	1.7	4
13	The quest to develop an effective therapy for neuroblastoma. Journal of Cellular Physiology, 2021, 236, 7775-7791.	2.0	12
14	Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
15	Cell competition in intratumoral and tumor microenvironment interactions. EMBO Journal, 2021, 40, e107271.	3.5	48
16	Flower lose, a cell fitness marker, predicts COVIDâ€19 prognosis. EMBO Molecular Medicine, 2021, 13, e13714.	3.3	4
17	SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress. Life Sciences, 2021, 287, 120141.	2.0	5
18	Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic. Seminars in Cancer Biology, 2020, 66, 140-154.	4.3	45

#	Article	IF	CITATIONS
19	MDA-9/Syntenin (SDCBP) Is a Critical Regulator of Chemoresistance, Survival and Stemness in Prostate Cancer Stem Cells. Cancers, 2020, 12, 53.	1.7	27
20	Vascular mimicry: Triggers, molecular interactions and in vivo models. Advances in Cancer Research, 2020, 148, 27-67.	1.9	47
21	Identification of Annexin A2 as a key mTOR target to induce roller coaster pattern of autophagy fluctuation in stress. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165952.	1.8	6
22	Cell Competition Boosts Clonal Evolution and Hypoxic Selection in Cancer. Trends in Cell Biology, 2020, 30, 967-978.	3.6	17
23	Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12324-12331.	3.3	28
24	MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein. Cancer and Metastasis Reviews, 2020, 39, 769-781.	2.7	23
25	EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells. Advances in Cancer Research, 2020, 147, 161-188.	1.9	77
26	Influenza virus NS1- C/EBPβ gene regulatory complex inhibits RIG-I transcription. Antiviral Research, 2020, 176, 104747.	1.9	7
27	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacological Research, 2020, 155, 104695.	3.1	29
28	Transcriptional regulation of HSPB1 by Friend leukemia integration-1 factor modulates radiation and temozolomide resistance in glioblastoma. Oncotarget, 2020, 11, 1097-1108.	0.8	15
29	Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin. Oncogene, 2019, 38, 6781-6793.	2.6	24
30	Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor. Molecular Cancer Therapeutics, 2019, 18, 1997-2007.	1.9	19
31	Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule. ACS Chemical Neuroscience, 2019, 10, 1121-1123.	1.7	12
32	Immunometabolism: A new target for improving cancer immunotherapy. Advances in Cancer Research, 2019, 143, 195-253.	1.9	30
33	Can CpG methylation serve as surrogate markers for immune infiltration in cancer?. Advances in Cancer Research, 2019, 143, 351-384.	1.9	19
34	MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis. Advances in Cancer Research, 2019, 144, 137-191.	1.9	17
35	MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5687-5692.	3.3	24
36	Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis. Cancer Letters, 2019, 452, 254-263.	3.2	25

#	Article	IF	CITATIONS
37	Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors. Advances in Cancer Research, 2019, 142, 107-143.	1.9	10
38	Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting. Advances in Cancer Research, 2019, 141, 43-84.	1.9	114
39	Mechanism of internalization of MDA-7/IL-24 protein and its cognate receptors following ligand-receptor docking. Oncotarget, 2019, 10, 5103-5117.	0.8	6
40	Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo. Cell Death and Disease, 2018, 9, 449.	2.7	12
41	Cancer terminator viruses (<i>CTV</i>): A better solution for viralâ€based therapy of cancer. Journal of Cellular Physiology, 2018, 233, 5684-5695.	2.0	13
42	Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer. Advances in Cancer Research, 2018, 137, 37-75.	1.9	153
43	The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Research, 2018, 78, 2852-2863.	0.4	37
44	Wnt7a and miR-370-3p: new contributors to bladder cancer invasion. Biotarget, 2018, 2, 14-14.	0.5	1
45	Astrocyte Elevated Gene-1 Regulates Macrophage Activation in Hepatocellular Carcinogenesis. Cancer Research, 2018, 78, 6436-6446.	0.4	22
46	Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica–Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Molecular Pharmaceutics, 2018, 15, 2698-2713.	2.3	29
47	New Insights Into Beclin-1: Evolution and Pan-Malignancy Inhibitor Activity. Advances in Cancer Research, 2018, 137, 77-114.	1.9	19
48	Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases. Advances in Cancer Research, 2018, 138, 143-182.	1.9	38
49	Prospects of Gene Therapy to Treat Melanoma. Advances in Cancer Research, 2018, 138, 213-237.	1.9	17
50	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the United States of America, 2018, 115, 5768-5773.	3.3	91
51	Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway. Molecular Cancer Therapeutics, 2018, 17, 1951-1960.	1.9	23
52	Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene, 2018, 37, 4546-4561.	2.6	61
53	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy, 2018, 14, 1845-1846.	4.3	30
54	Reply to Yoshida: Delineating critical roles of MDA-9 in protective autophagy-mediated anoikis resistance in human glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7654-E7655.	3.3	2

#	Article	IF	CITATIONS
55	The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. Hepatoma Research, 2018, 4, 32.	0.6	16
56	Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma. Cancer Research, 2017, 77, 3306-3316.	0.4	42
57	A novel role of astrocyte elevated geneâ€1 (AEGâ€1) in regulating nonalcoholic steatohepatitis (NASH). Hepatology, 2017, 66, 466-480.	3.6	35
58	Astrocyte Elevated Gene-1 Regulates β-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal. Molecular Cancer Research, 2017, 15, 225-233.	1.5	24
59	IGFBP7 Deletion Promotes Hepatocellular Carcinoma. Cancer Research, 2017, 77, 4014-4025.	0.4	44
60	Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer Letters, 2017, 388, 292-302.	3.2	65
61	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 370-375.	3.3	79
62	<i>mda-7/IL-24</i> Mediates Cancer Cell–Specific Death via Regulation of miR-221 and the Beclin-1 Axis. Cancer Research, 2017, 77, 949-959.	0.4	47
63	Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment. Langmuir, 2017, 33, 7649-7659.	1.6	35
64	HIV induces expression of complement component C3 in astrocytes by NF-κB-dependent activation of interleukin-6 synthesis. Journal of Neuroinflammation, 2017, 14, 23.	3.1	32
65	The Enigma of miRNA Regulation in Cancer. Advances in Cancer Research, 2017, 135, 25-52.	1.9	37
66	MDA-9/Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 <i>via</i> transforming growth factor l²1 to enhance epithelial-mesenchymal transition in breast cancer. Oncotarget, 2016, 7, 80175-80189.	0.8	35
67	Tetraspanin 8 mediates <scp>AEG</scp> â€lâ€induced invasion and metastasis in hepatocellular carcinoma cells. FEBS Letters, 2016, 590, 2700-2708.	1.3	24
68	<i>Abrus</i> agglutinin is a potent antiâ€proliferative and antiâ€angiogenic agent in human breast cancer. International Journal of Cancer, 2016, 139, 457-466.	2.3	24
69	AEC-1 promotes mesenchymal transition through the activation of Rho GTPases in human glioblastoma cells. Oncology Reports, 2016, 36, 2641-2646.	1.2	13
70	<i>mda-7/IL-24</i> Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM. Cancer Research, 2016, 76, 3572-3582.	0.4	30
71	Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. Oncolmmunology, 2016, 5, e1078059.	2.1	7
72	Preface. Advances in Cancer Research, 2016, 132, xi-xiv.	1.9	2

#	Article	IF	CITATIONS
73	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
74	Critical Length of PEG Grafts on IPEI/DNA Nanoparticles for Efficient in Vivo Delivery. ACS Biomaterials Science and Engineering, 2016, 2, 567-578.	2.6	43
75	Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL). Journal of Biological Chemistry, 2016, 291, 10736-10746.	1.6	33
76	Activation of the MDA-5–IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity. Cancer Research, 2016, 76, 2166-2176.	0.4	32
77	Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis. Oncotarget, 2016, 7, 46848-46861.	0.8	28
78	Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells. Oncotarget, 2016, 7, 54102-54119.	0.8	25
79	Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget, 2016, 7, 17103-17110.	0.8	25
80	Tumorâ€specific expression and detection of a CEST reporter gene. Magnetic Resonance in Medicine, 2015, 74, 544-549.	1.9	44
81	The role of AEG-1 in the development of liver cancer. Hepatic Oncology, 2015, 2, 303-312.	4.2	20
82	Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets. Advances in Cancer Research, 2015, 127, 49-121.	1.9	25
83	The Quest for an Effective Treatment for an Intractable Cancer. Advances in Cancer Research, 2015, 127, 283-306.	1.9	10
84	Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. Cancer Research, 2015, 75, 2305-2315.	0.4	34
85	AEC-1–AKT2: A novel complex controlling the aggressiveness of glioblastoma. Molecular and Cellular Oncology, 2015, 2, e995008.	0.3	11
86	Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Molecular Pharmaceutics, 2015, 12, 4214-4225.	2.3	68
87	Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (Review). International Journal of Oncology, 2015, 46, 465-473.	1.4	60
88	Reversing Translational Suppression and Induction of Toxicity in Pancreatic Cancer Cells Using a Chemoprevention Gene Therapy Approach. Molecular Pharmacology, 2015, 87, 286-295.	1.0	8
89	Astrocyte Elevated Gene-1 (AEG-1) Regulates Lipid Homeostasis. Journal of Biological Chemistry, 2015, 290, 18227-18236.	1.6	18
90	Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All- <i>trans</i> Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). Bioconjugate Chemistry, 2015, 26, 1651-1661.	1.8	44

#	Article	IF	CITATIONS
91	Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression. Scientific Reports, 2015, 5, 11760.	1.6	66
92	Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chemistry and Biology, 2015, 22, 876-887.	6.2	29
93	Scavenger Receptors. Advances in Cancer Research, 2015, 128, 309-364.	1.9	90
94	Astrocyte Elevated Gene-1 (AEG-1) Contributes to Non-thyroidal Illness Syndrome (NTIS) Associated with Hepatocellular Carcinoma (HCC). Journal of Biological Chemistry, 2015, 290, 15549-15558.	1.6	20
95	Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness. Neuro-Oncology, 2015, 17, 419-429.	0.6	65
96	Gene Therapies for Cancer: Strategies, Challenges and Successes. Journal of Cellular Physiology, 2015, 230, 259-271.	2.0	179
97	Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic. Oncotarget, 2015, 6, 10712-10727.	0.8	27
98	Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget, 2015, 6, 16623-16637.	0.8	50
99	Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model. Oncotarget, 2015, 6, 26266-26277.	0.8	23
100	Suppression of Her2/Neu mammary tumor development in <i>mda-7/IL-24</i> transgenic mice. Oncotarget, 2015, 6, 36943-36954.	0.8	14
101	MDA-7/IL-24 functions as a tumor suppressor gene <i>in vivo</i> in transgenic mouse models of breast cancer. Oncotarget, 2015, 6, 36928-36942.	0.8	34
102	Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction. Journal of Personalized Nano Medicine, 2015, 1, 3-9.	0.8	8
103	Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 9.	1.8	5
104	AEC-1 Regulates Retinoid X Receptor and Inhibits Retinoid Signaling. Cancer Research, 2014, 74, 4364-4377.	0.4	39
105	Genetic Deletion of AEG-1 Prevents Hepatocarcinogenesis. Cancer Research, 2014, 74, 6184-6193.	0.4	47
106	Pancreatic Cancer–Specific Cell Death Induced <i>In Vivo</i> by Cytoplasmic-Delivered Polyinosine–Polycytidylic Acid. Cancer Research, 2014, 74, 6224-6235.	0.4	38
107	In Vivo Modeling of Malignant Glioma. Advances in Cancer Research, 2014, 121, 261-330.	1.9	21
108	Novel Mechanism of MDA-7/IL-24 Cancer-Specific Apoptosis through SARI Induction. Cancer Research, 2014, 74, 563-574.	0.4	41

#	Article	IF	CITATIONS
109	Astrocyte Elevated Gene-1 Interacts with Akt Isoform 2 to Control Glioma Growth, Survival, and Pathogenesis. Cancer Research, 2014, 74, 7321-7332.	0.4	56
110	AEG-1 Promoter–Mediated Imaging of Prostate Cancer. Cancer Research, 2014, 74, 5772-5781.	0.4	33
111	Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer. Advances in Cancer Research, 2014, 121, 331-382.	1.9	28
112	Molecular-Genetic Imaging of Cancer. Advances in Cancer Research, 2014, 124, 131-169.	1.9	20
113	MDA-7/IL-24: Multifunctional Cancer Killing Cytokine. Advances in Experimental Medicine and Biology, 2014, 818, 127-153.	0.8	104
114	Staphylococcal nuclease domain containingâ€l (SND1) promotes migration and invasion via angiotensin Il type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio, 2014, 4, 353-361.	1.0	41
115	Characterization of the canine mda-7 gene, transcripts and expression patterns. Gene, 2014, 547, 23-33.	1.0	2
116	Evolutionary dynamics of Polynucelotide phosphorylases. Molecular Phylogenetics and Evolution, 2014, 73, 77-86.	1.2	2
117	MDA-9/Syntenin regulates differentiation and angiogenesis programs in head and neck squamous cell carcinoma. Oncoscience, 2014, 1, 725-737.	0.9	24
118	Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3- <i>CTV</i>). Journal of Cellular Physiology, 2013, 229, n/a-n/a.	2.0	21
119	AEG-1/MTDH/LYRIC, the Beginning. Advances in Cancer Research, 2013, 120, 1-38.	1.9	55
120	AEG-1/MTDH/LYRIC. Advances in Cancer Research, 2013, 120, 75-111.	1.9	87
121	Autophagy. Advances in Cancer Research, 2013, 118, 61-95.	1.9	161
122	MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma. Cancer Research, 2013, 73, 844-854.	0.4	78
123	Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. International Journal of Cancer, 2013, 133, n/a-n/a.	2.3	36
124	Novel Role of MDA-9/Syntenin in Regulating Urothelial Cell Proliferation by Modulating EGFR Signaling. Clinical Cancer Research, 2013, 19, 4621-4633.	3.2	54
125	Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology and Therapy, 2013, 14, 1039-1049.	1.5	21
126	Histone Deacetylase Inhibitors Interact with Melanoma Differentiation Associated-7/Interleukin-24 to Kill Primary Human Glioblastoma Cells. Molecular Pharmacology, 2013, 84, 171-181.	1.0	21

#	Article	IF	CITATIONS
127	Innovative approaches for enhancing cancer gene therapy. Discovery Medicine, 2013, 15, 309-17.	0.5	13
128	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
129	Enhanced delivery of <i>mdaâ€</i> 7/ILâ€24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative Blâ€97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology, 2012, 227, 2145-2153.	2.0	43
130	Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes. Advances in Cancer Research, 2012, 115, 1-38.	1.9	26
131	Loss of α SNAP induces colonic epithelial cell apoptosis via downâ€regulation of Bclâ€2 expression and fragmentation of the Colgi. FASEB Journal, 2012, 26, 655.9.	0.2	0
132	Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nature Medicine, 2011, 17, 123-129.	15.2	84
133	A Serotype 5/3 Adenovirus Expressing MDA-7/IL-24 Infects Renal Carcinoma Cells and Promotes Toxicity of Agents That Increase Ros and Ceramide Levels. Molecular Pharmacology, 2011, 79, 368-380.	1.0	28
134	Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (<i>mda</i> -7/IL-24). Autophagy, 2011, 7, 1076-1077.	4.3	42
135	Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to <i>mda</i> -7/IL-24–mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8785-8790.	3.3	112
136	Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discovery Medicine, 2011, 11, 46-56.	0.5	23
137	Ceramide plays a prominent role in MDAâ€7/ILâ€24â€induced cancerâ€specific apoptosis. Journal of Cellular Physiology, 2010, 222, 546-555.	2.0	54
138	MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anti-Cancer Drugs, 2010, 21, 725-731.	0.7	48
139	The development of MDA-7/IL-24 as a cancer therapeutic. , 2010, 128, 375-384.		54
140	Melanoma Differentiation Associated Gene-7/Interleukin-24 Potently Induces Apoptosis in Human Myeloid Leukemia Cells through a Process Regulated by Endoplasmic Reticulum Stress. Molecular Pharmacology, 2010, 78, 1096-1104.	1.0	34
141	Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24–Induced Killing in Ovarian Carcinoma Cells. Molecular Pharmacology, 2010, 77, 298-310.	1.0	33
142	Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway. Journal of Biological Chemistry, 2010, 285, 10064-10077.	1.6	57
143	Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine. Cancer Research, 2010, 70, 5034-5045.	0.4	66
144	Enhancing <i>mda</i> -7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biology and Therapy, 2010, 10, 1290-1305.	1.5	27

#	Article	IF	CITATIONS
145	Eradication of Therapy-resistant Human Prostate Tumors Using an Ultrasound-guided Site-specific Cancer Terminator Virus Delivery Approach. Molecular Therapy, 2010, 18, 295-306.	3.7	67
146	mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine and Growth Factor Reviews, 2010, 21, 381-391.	3.2	95
147	Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma. Molecular Therapy, 2010, 18, 1130-1142.	3.7	40
148	PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in <i>mda</i> -7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells. Cancer Research, 2010, 70, 1120-1129.	0.4	95
149	Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biology and Therapy, 2009, 8, 402-411.	1.5	81
150	MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism. Molecular Cancer Therapeutics, 2009, 8, 1280-1291.	1.9	44
151	Mechanism of <i>In vitro</i> Pancreatic Cancer Cell Growth Inhibition by Melanoma Differentiation–Associated Gene-7/Interleukin-24 and Perillyl Alcohol. Cancer Research, 2008, 68, 7439-7447.	0.4	38
152	Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Molecular Cancer Therapeutics, 2008, 7, 314-329.	1.9	42
153	Autocrine regulation of <i>mda</i> -7/IL-24 mediates cancer-specific apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9763-9768.	3.3	114
154	PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy, 2008, 4, 513-515.	4.3	53
155	MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology and Therapy, 2008, 7, 917-933.	1.5	44
156	Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Molecular Cancer Therapeutics, 2008, 7, 2042-2050.	1.9	31
157	Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Molecular Cancer Therapeutics, 2008, 7, 297-313.	1.9	71
158	Melanoma differentiation associated gene-7 (mda-7)/IL-24: a â€~magic bullet' for cancer therapy?. Expert Opinion on Biological Therapy, 2007, 7, 577-586.	1.4	49
159	Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. Molecular Cancer Therapeutics, 2007, 6, 2985-2994.	1.9	30
160	Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3484-3489.	3.3	39
161	A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus σ1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor–Independent Pathway. Clinical Cancer Research, 2007, 13, 2777-2783.	3.2	23
162	Eradication of Therapy-Resistant Human Prostate Tumors Using a Cancer Terminator Virus. Cancer Research, 2007, 67, 5434-5442.	0.4	78

#	Article	IF	CITATIONS
163	Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): Novel gene therapeutic for metastatic melanoma. Toxicology and Applied Pharmacology, 2007, 224, 300-307.	1.3	78
164	mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology, 2007, 31, 985-1007.	1.4	52
165	Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecologic Oncology, 2006, 100, 521-532.	0.6	32
166	mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. , 2006, 111, 596-628.		164
167	Unique Conditionally Replication Competent Bipartite Adenoviruses—Cancer Terminator Viruses (CTV): Efficacious Reagents for Cancer Gene Therapy. Cell Cycle, 2006, 5, 1531-1536.	1.3	23
168	Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene, 2005, 24, 585-596.	2.6	66
169	Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3). Oncogene, 2005, 24, 2247-2255.	2.6	23
170	Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene, 2005, 24, 7552-7566.	2.6	137
171	Progression elevated gene-3 (PEC-3) induces pleiotropic effects on tumor progression: Modulation of genomic stability and invasion. Journal of Cellular Physiology, 2005, 202, 135-146.	2.0	18
172	Targeted Virus Replication Plus Immunotherapy Eradicates Primary and Distant Pancreatic Tumors in Nude Mice. Cancer Research, 2005, 65, 9056-9063.	0.4	50
173	Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1059-1064.	3.3	78
174	Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14034-14039.	3.3	117
175	Is mda-7/IL-24 a "Magic Bullet―for Cancer?. Cancer Research, 2005, 65, 10128-10138.	0.4	201
176	Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene, 2005, 353, 8-15.	1.0	264
177	Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. Journal of Cellular Physiology, 2003, 196, 334-345.	2.0	89
178	Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene, 2003, 22, 1164-1180.	2.6	168
179	Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene, 2003, 22, 8758-8773.	2.6	125
180	MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine and Growth Factor Reviews, 2003, 14, 35-51.	3.2	148

#	Article	IF	CITATIONS
181	mda-7(IL-24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells In Vitro via JNK Signaling. Cancer Biology and Therapy, 2003, 2, 347-353.	1.5	94
182	mda-7/IL-24, A Novel Cancer Selective Apoptosis Inducing Cytokine Gene: From the Laboratory into the Clinic. Cancer Biology and Therapy, 2003, 2, 22-36.	1.5	161
183	MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Molecular Cancer Therapeutics, 2003, 2, 623-32.	1.9	47
184	mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biology and Therapy, 2003, 2, S23-37.	1.5	77
185	Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Research, 2003, 63, 8138-44.	0.4	83
186	<i>mda</i> -7 (IL-24): Signaling and Functional Roles. BioTechniques, 2002, 33, S30-S39.	0.8	60
187	The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene, 2002, 21, 708-718.	2.6	194
188	mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10054-10059.	3.3	288
189	mda-7 (IL-24): signaling and functional roles. BioTechniques, 2002, Suppl, 30-9.	0.8	14
190	Melanoma Differentiation Associated Gene-7 (mda-7): A Novel Anti-Tumor Gene for Cancer Gene Therapy. Molecular Medicine, 2001, 7, 271-282.	1.9	155
191	Molecular markers and determinants of prostate cancer metastasis. Journal of Cellular Physiology, 2001, 189, 245-256.	2.0	56
192	Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MDA6 and p27Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology, 2001, 34, 906-917.	3.6	59
193	Ionizing radiation modulates vascular endothelial growth factor (VECF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene, 2001, 20, 3266-3280.	2.6	121
194	Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20, 7051-7063.	2.6	204
195	AP-1 and C/EBP transcription factors contribute tomda-7 gene promoter activity during human melanoma differentiation. Journal of Cellular Physiology, 2000, 185, 36-46.	2.0	44
196	Regulation of mda-7 gene expression during human melanoma differentiation. Oncogene, 2000, 19, 1362-1368.	2.6	51
197	Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene, 2000, 19, 3411-3421.	2.6	45
198	Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human Galectin-8 related gene. Oncogene, 2000, 19, 4405-4416.	2.6	52

#	Article	IF	CITATIONS
199	AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. , 2000, 185, 36.		1
200	α-Adrenergic inhibition of proliferation in HepG2 cells stably transfected with the α1B-adrenergic receptor through a p42MAPâ€^kinase/p21Cip1/WAF1-dependent pathway. FEBS Letters, 1998, 436, 131-138.	1.3	27
201	Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. Biochemical Journal, 1998, 336, 551-560.	1.7	64
202	Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-β. Oncogene, 1997, 14, 473-480.	2.6	42
203	Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. , 1996, 15, 284-299.		67
204	Induction of growth suppression and modification of gene expression in multi-drug-resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon. International Journal of Cancer, 1992, 51, 373-378.	2.3	4
205	Induction and progression of the transformed phenotype in cloned rat embryo fibroblast cells: Studies employing type 5 adenovirus and wild-type and mutant Ha-ras oncogenes. Molecular Carcinogenesis, 1992, 5, 118-128.	1.3	8
206	Suppression of adenovirus type 5 E1A-mediated transformation and expression of the transformed phenotype by caffeic acid phenethyl ester (CAPE). Molecular Carcinogenesis, 1991, 4, 231-242.	1.3	50
207	Low-level β1 protein kinase C expression in cloned rat embryo fibroblast cells enhances transformation induced by the adenovirus type 5 E1A gene. Molecular Carcinogenesis, 1991, 4, 328-337.	1.3	4
208	Enhancement of viral and DNA mediated transformation of cloned rat embryo fibroblast cells by 3-aminobenzamide. Molecular Carcinogenesis, 1990, 3, 309-318.	1.3	10
209	Modulation of the Antigenic Phenotype of Human Melanoma Cells by Differentiationâ€inducing and Growthâ€suppressing Agents. Pigment Cell & Melanoma Research, 1990, 3, 123-131.	4.0	10
210	Mutations in the E1a gene of type 5 adenovirus result in oncogenic transformation of fischer rat embryo cells. Journal of Cellular Biochemistry, 1987, 33, 117-126.	1.2	7
211	Regulation of thyroidal inducibility of Na,K-ATPase and binding of epidermal growth factor in wild-type and cold-sensitive E1a mutant type 5 adenovirus-transformed CREF cells. Journal of Cellular Physiology, 1987, 133, 507-514.	2.0	4
212	Effects of Combined Treatment with Interferon and Mezerein on Melanogenesis and Growth in Human Melanoma Cells. Journal of Interferon Research, 1985, 5, 11-22.	1.2	108
213	Metastasis-Promoting Genes. , 0, , 55-63.		1